Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
J Gastrointest Cancer
; 55(3): 1448-1452, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38814411
ABSTRACT
PURPOSE:
Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3.METHODS:
This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue.RESULTS:
This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T.CONCLUSION:
Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Oximas
/
Neoplasias Pancreáticas
/
Piridonas
/
Pirimidinonas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tumores Neuroendocrinos
/
Proteínas Proto-Oncogénicas B-raf
/
Imidazoles
/
Mutación
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Gastrointest Cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos